Loading…
No business profile yet.
Size Taidoc Technology (4736.TW) is a Taiwan Health Care company (Medical Specialties) with a market value of $395M, the 529th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$126.00 on 6 Nov 2026.
Performance Over six months the shares gained 0.4%, against -21.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +16.2%); the operating margin is 17.8% (peer median 8.0%).
Valuation It trades at 1.9× enterprise value to sales against a peer median of 5.0× (7th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$4.23B | NT$4.20B | NT$4.64B | NT$4.81B | NT$9.63B |
| Revenue growth | — | -9% | -3% | -50% | — |
| Gross profit | NT$1.77B | NT$1.90B | NT$2.01B | NT$2.02B | NT$5.59B |
| EBITDA | NT$890M | NT$1.10B | NT$979M | NT$1.20B | NT$4.37B |
| Net income | NT$2.56B | NT$1.44B | NT$1.16B | NT$1.02B | NT$3.38B |
| Free cash flow | NT$796M | NT$739M | NT$734M | NT$1.28B | NT$3.77B |
| Capital expenditure | NT$276M | NT$251M | NT$355M | NT$114M | NT$508M |
| Total debt | NT$941M | NT$1.16B | NT$1.05B | NT$1.09B | NT$636M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4736.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.9% | -15.1% | 7th highest of 21 |
| 6-month return | +0.4% | -21.4% | 4th highest of 19 |
| Distance from 52-week high | -13.7% | -42.3% | highest of 21 |
| Revenue growth (TTM) | -6.0% | +16.2% | 4th lowest of 20 |
| Operating margin | 17.8% | 8.0% | 6th highest of 20 |
| EV / Sales | 1.9× | 5.0× | 7th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -8.0% | 3.6% | 5th least demanding of 13 |
| Growth delivered (Del g) | -6.6% | +4.8% | lowest of 13 |
| Hurdle (Req g minus delivered) | -1.5 pp | +4.4 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +4.4 pp | -0.3 pp | 9th highest of 18 |
| EV / EBITDA | 9.1× | 9.1× | 4th most expensive of 8 |
| Net debt / EBITDA | -6.0× | -3.6× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | 1.9× | -8.0% | -6.6% |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 1.0× | -18.5% | +15.4% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 5.0× | 39.0% | +5.2% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | 1.9× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 5.4× | 9.8% | +3.4% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 6.0× | 20.0% | +4.4% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | 1.6× | 23.3% | +18.1% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 1.4× | -7.6% | +16.9% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 8.0× | 22.4% | -5.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 8.1× | 55.5% | +3.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | 704.2× | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | 8.0× | n/a | n/a |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | 5.7× | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |